Is It Time To Reassess Medline (MDLN) After Recent Share Price Swings?

• Wondering whether Medline at US$37.01 is pricing in too much optimism or not enough? This article walks through what that price could mean for you as an investor focused on value.
• Over the past week the stock gained 2.3%, but over the last month it fell 21.5%, leaving it down 8.9% year to date.
• These moves have come alongside ongoing interest in Medline as a listed healthcare company, with investors paying closer attention to how its fundamentals line up with its current share price. The following sections focus on what the data says about valuation rather than short term headlines.
• Medline currently scores 3 out of 6 on Simply Wall St's valuation checks, giving it a value score of 3. The next sections walk through traditional valuation approaches before circling back to a more detailed way to think about what the stock could be worth.

Medline delivered 0.0% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Approach 1: Medline Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required rate of return. It focuses on the cash the business might generate for shareholders rather than short term earnings moves.

For Medline, the model starts with last twelve month Free Cash Flow of about $1.05b. Analyst and model projections then step this up over time, with forecast Free Cash Flow of $3.36b in 2030. The ten year path to that point blends analyst inputs for the earlier years with extrapolated figures beyond the analyst horizon, which is typically up to five years.

Feeding these projections into a 2 Stage Free Cash Flow to Equity model gives an estimated intrinsic value of about $46.57 per share. Compared with the current share price of $37.01, the DCF output suggests Medline trades at a 20.5% discount to this estimate. On this cash flow view, the stock appears to be trading below the model’s estimate of intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Medline is undervalued by 20.5%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Medline.

Approach 2: Medline Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings. It helps you compare Medline’s valuation with other stocks using the same earnings based yardstick.

In general, higher growth expectations and lower perceived risk tend to be associated with higher “normal” P/E ratios, while slower growth or higher risk often come with lower multiples. Medline currently trades on a P/E of 32.40x. This is above the Medical Equipment industry average of 24.53x and also above the peer group average of 22.75x.

Simply Wall St’s Fair Ratio is a proprietary estimate of what Medline’s P/E might be given its earnings growth profile, industry, profit margins, market cap and specific risks. This is more tailored than a simple comparison with peers or the industry, because it factors in company level characteristics rather than assuming all stocks deserve similar multiples. With no Fair Ratio available here, there is not enough information to say whether Medline’s 32.40x P/E suggests the stock is overvalued, undervalued or roughly in line with that model.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Medline Narrative

Earlier it was mentioned that there is an even better way to think about valuation. Narratives let you turn your view of Medline into a clear story that links its business drivers and assumptions about future revenue, earnings and margins to a forecast and fair value. They then compare that fair value with the current price to help you decide what to do, all within an easy tool on Simply Wall St’s Community page that updates as new news or earnings arrive. One investor might build a Medline Narrative around the higher analyst fair value of about US$60.0 if they think the catalysts and margin expansion are achievable, while another might anchor closer to US$40.0 if they are more cautious about execution and risks.

Do you think there's more to the story for Medline? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com